Continuous integrated manufacturing of therapeutic proteins
- 1 October 2018
- journal article
- review article
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 53, 76-84
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor™. Part I. Effect of the cell density on the processBiotechnology Progress, 2013
- Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approachBiotechnology Progress, 2012
- Effects of cell culture conditions on antibody N‐linked glycosylation—what affects high mannose 5 glycoformBiotechnology and Bioengineering, 2011
- Increasing the activity of monoclonal antibody therapeutics by continuous chromatography (MCSGP)Biotechnology and Bioengineering, 2010
- Assessing monoclonal antibody product quality attribute criticality through clinical studiesmAbs, 2010
- Optimal and consistent protein glycosylation in mammalian cell cultureGlycobiology, 2009
- Heterogeneity of Monoclonal AntibodiesJournal of Pharmaceutical Sciences, 2008
- A continuous multicolumn countercurrent solvent gradient purification (MCSGP) processBiotechnology and Bioengineering, 2007
- The Impact of Glycosylation on the Biological Function and Structure of Human ImmunoglobulinsAnnual Review of Immunology, 2007
- Optimisation of the Cellular Metabolism of Glycosylation for Recombinant Proteins Produced by Mammalian Cell SystemsCytotechnology, 2005